Alnylam inks another Japanese development pact

Cambridge, MA-based Alnylam Pharmaceuticals has signed on to a $93 million pact with Japan's Kyowa Hakko Kogyo to develop an Respiratory Syncytial Virus therapy for Asian markets. Alnylam gets $15 million of that up front with a lineup of $78 million in milestones. Alnylam will also get double-digit royalties from Kyowa Hakko based on the sales of ALN-RSV01 in Asia. The partnership also includes additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program. Alnylam retains all development and commercialization rights worldwide excluding Asia.

"This new collaboration is yet another example of Alnylam's commitment to work with leading biotechnology and pharmaceutical companies to advance RNAi therapeutics to patients on a global basis," said Alnylam CEO John Maraganore. This is Alnylam's second deal with a Japanese pharma company in a matter of weeks.

- see Alnylam's release
- read the report from the Boston Globe

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."